PAVmed Inc. (NASDAQ: PAVM) appointed Joseph Virgilio as Senior Vice President and Chief Business Officer for Medical Devices to oversee development and commercialization of the company's medical device portfolio.

Virgilio brings more than 25 years of medical device industry experience, including roles at Morphic Medical, where he served as President and CEO, and previous positions at Boston Scientific Inc. and Medtronic Inc. At Morphic Medical, he led regulatory initiatives including EU approvals and a U.S. FDA pre-market authorization study while securing over $40 million in capital.

The appointment coincides with PAVmed's relaunch of its medical device portfolio, which includes the PortIO implantable intraosseous vascular access device and endoscopic imaging technology licensed from Duke University. The company formed a new subsidiary, Octeris Inc., to advance the Duke-licensed technology designed to identify esophageal dysplasia during upper endoscopy.

Virgilio will serve as CEO of both PortIO Inc. and Octeris Inc., the subsidiaries housing these medical device programs. PAVmed previously executed a definitive license agreement with Duke University for the endoscopic technology following an earlier letter of intent.

"Fixing PAVmed's capital structure and strengthening our balance sheet has allowed us to proceed with the long-anticipated relaunch our medical device portfolio under dedicated, experienced leadership," said PAVmed Chairman and CEO Lishan Aklog.

PAVmed operates as a diversified medical technology company with subsidiaries including Lucid Diagnostics Inc. (NASDAQ: LUCD), which markets esophageal cancer screening tools, and Veris Health Inc., focused on digital health solutions for cancer care.